The Multiple Sclerosis Association of America (MSAA), founded in 1970, is proud to recognize its 50th Anniversary in 2020 as a nonprofit organization dedicated to supporting the multiple sclerosis community […]
Read News ArticleAuthor: Hoff Communications
What’s New in MS Research: January 2020
To live with multiple sclerosis (MS) is to cope with the challenges it presents and to look forward to the promise of ongoing progress in understanding and managing the condition. This edition of “What’s New in MS Research” reflects that mix of obstacles and opportunities.
Read News Article
MSAA Debuts New Logo and Website Design
The Multiple Sclerosis Association of America (MSAA) is pleased to introduce our new logo and redesigned website homepage! As we enter our 50th year of dedicated service to the MS […]
Read News ArticleWhat is Multiple Sclerosis?
Multiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. It is an unpredictable disorder that can cause […]
Read News ArticleWhat We Do
MSAA improves lives today for the multiple sclerosis (MS) community through our free programs and services. Learn more about what we offer and how to access these vital resources. Toll-Free […]
Read News ArticleHelpline FAQs
What services are offered through MSAA’s Helpline? MSAA provides a toll-free Helpline that allows individuals with MS, family members, care partners, and friends to speak directly with one of MSAA’s […]
Read News ArticleMSAA Announces New Chairperson of Healthcare Advisory Council
The Multiple Sclerosis Association of America (MSAA) is proud to announce the new Chairperson of the Healthcare Advisory Council for the organization. Dr. Carrie Hersh, a multiple sclerosis specialist at […]
Read News ArticleWho We Are
MSAA’s Mission and Overview Making an Impact: How MSAA is Improving Lives Today View PDF MSAA… Improving Lives Today! The Multiple Sclerosis Association of America (MSAA) is a leading resource […]
Read News ArticleFDA Approves Generic Versions of Gilenya®
On December 5, 2019, the United States Food and Drug Administration (FDA) announced that they had approved the applications from three separate pharmaceutical companies for the first generic versions of Gilenya® (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.
Read News Article